

Correlation Between Systemic Lupus Erythematosus and Renal Damage

Elita Zylbeari-Masha^{1,4}, Gazmend Zylbeari¹, Zamira Bexheti³, Art Zylbeari^{1,4},
Bistra Angelovska², Lutfi Zylbeari^{1*}

Received: 21 January 2024 / Accepted: 13 February 2024 / Published online: 20 July 2024

This article is published with open access at <https://journal.astes.org.al>

© The author(s) 2024. & Copyright © 2024, the Albanian Society for Trauma and Emergency Surgery

© The Albanian Journal of Trauma and Emergency Surgery is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License: <http://creativecommons.org/licenses/by-nc/4.0/> which permits unrestricted non-commercial use, distribution, and reproduction in any medium provided the original work is properly cited.

Abstract

Introduction: Two of the most frequent Lupus nephritis (LN) diseases are multiple glomerulonephritis and renal fibrosis. Recent studies have verified that 10-30% of patients with SLE after several years (3-6 years) develop LN and end-stage chronic renal disease (ESRD) when there is a need for chronic intermittent hemodialysis (HD) treatment. [1, 2, 3]

The paper aimed to assess renal damage due to LN using the results obtained from the examined parameters in patients with chronic kidney disease (CKD) in the third stage (a and b).

Materials and Methods: This prospective cohort research (cross-section “”) study included 100 patients with CKD (55 were men with an average age of 57.00±8.50 years old with chronic renal disease, 20 with diabetes mellitus (DM) and nephropathy diabetics, 15 were arterial hypertension (AHT), 11 were with chronic glomerulonephritis (CGN), 3 with Adult polycystic kidney disease (APCKD) and six patients were with undefined renal disease, while 45 were female with an average age of 55.80 ±10.50 years old), with primary kidney disease: 16-with diabetes mellitus and diabetic nephropathy, 11 with HTA...

Statistical analysis of the examined material: The obtained results from the studied patients with CKD and the control group were statistically processed with arithmetic mean value, standard deviation $X \pm SD$, with Student, “t” test, Mann-Whitney and Wilcoxon test. The results were processed with the appropriate state-of-the-art statistical program, SPSS V26.

Results Tables and graphs 4 and 8 present the results obtained at the beginning of the study (for all patients with LN and CKD: women and men) and after 12 months of treatment.

Conclusion: The results obtained suggest that LES affects the appearance of renal damage; therefore, early detection and treatment of the initial stages of LN influence the reduction of its activity.

Keywords: Lupus Nephritis, LES, Clinical manifestations, Renal damage.

Introduction

Systemic Lupus Erythematosus (SLE) is a chronic inflammatory disease of the connective tissue. It is multisystemic in nature and has an unknown etiology. SLE mainly affects women during their reproductive years and is characterized by damage to the joints, kidneys, and serous membranes, as well as antinuclear antibodies (ANA).

Renal damage is the leading cause of morbidity and hospitalization for a patient with SLE.

Renal damage appears within the first two years but also after five years of the disease.

According to the classification made according to histopathological findings by the International Society of Nephrology (ISN)/Renal Pathology Society (RPS), Kidney International, and Journal of the American Society of

Original article, no submission or publication in advance or in parallel

* Corresponding author:

Prof. Dr. Ord. Lutfi Zylbeari, MD, PhD

✉ dr-luti@hotmail.com

1 Faculty of Medical Sciences, University of Tetovo, Tetovo, North MACEDONIA

2 Faculty of Medical Sciences, Goce Delcev University, Stip, North MACEDONIA

3 Southeast European University- Tetovo, North MACEDONIA

4 Clinical Hospital, Tetovo, North MACEDONIA

Nephrology public-shed in February 2004, LN manifests with VI classes [4-7].

Global or segmental glomerular cicatrices that manifest as a chronic consequence of endocapillary glomerular proliferation, with the appearance of crescents, immunoglobulin deposits, and in the laboratory examination of urine for 24 hours, hematuria and proteinuria >150-3000 mg/24 hours appear, which symptoms should be counted as manifestations of LN [8].

The classification of lupus nephritis is based on kidney biopsy. Over time, LN can worsen and lead to end-stage chronic renal failure when treatment with chronic hemodialysis is imposed. Renal failure (acute or chronic) and sepsis are the two leading causes of death in patients with SLE.

LN affects 30-60% of adults and up to 70% of children. It is characterized by the deposition of immune complexes in the glomeruli, which is accompanied by inflammation and progresses until renal fibrosis appears [9, 10].

The symptoms of LN tend to develop about five years after the first appearance of symptoms. They are manifested by edema in the lower part of the body or around the eyes, fever without any known cause, hematuria, hypertension, nocturnal, oliguria, proteinuria, muscle pain, redness of the skin on the face (i.e., the form of "butterflies"), inappetence, etc. [11-15].

Chronic renal damage as a consequence of LN includes modifications of chromatin structure, DNA demethylation that regulates C3 production, histone acetylation that governs the production of profibrotic Platelet-derived growth factor (PDGF) genes, infiltration and activation of immune cells, extracellular matrix fibrosis, endothelial cell activation, fibrinolysis, mitochondrial dysfunction, and tubular damage [16].

Assessing renal function in patients with SLE is vital because early detection and treatment of renal involvement can significantly improve the outcome and course of renal disease [17].

Patients with SLE have poor clearance mechanisms for cellular debris and nuclear debris from apoptotic cells that induce plasmacytoid dendritic cells to produce interferon- α , which is a powerful promoter of the immune system and auto-immunity.

Autoreactive B lymphocytes, which are generally inactive during SLE, become active due to the malfunctioning of standard mechanisms homeostatic, resulting in a departure from tolerance.

This leads to the production of autoantibodies. Other autoantibodies, including anti-ds DNA antibodies, develop through epitope spreading.

These autoantibodies develop over time, typically months to years before the onset of clinical SLE.

Table 1 presents the classification of LES according to the International Society of Nephrology (ISN) / Renal Pathology Society and the Renal Pathology Society (RPS), 2003/2004.

Class I	Minimal mesangial LN
Class II	Mesangial proliferative LN
Class III	Focal LN (<50% of glomeruli)
Class III (A)	active lesions
Class III (A/C)	active and chronic lesions
Class III C	chronic lesions
Class IV	Diffuse LN ($\geq$ 50% of glomeruli).
Class IV-S) or global (IV-G) LN	Diffuse segmental (IV-S) or international (IV-G) LN
Class IV (A)	active lesions
Class IV (A/C)	active and chronic lesions
Class IV C	active and chronic lesions
Class V	Membranous LN
Class VI	Advanced sclerosing LN $\geq$ 90%, Globally without residual activity

Table 1. Classification of LES according to the International Society of Nephrology (ISN) / Renal Pathology Society and the Renal Pathology Society (RPS), 2003/2004.

The paper aimed to assess renal damage due to LN using the results obtained from the examined parameters in patients with CKD in the third stage (a and b).

Materials and Methods:

This prospective cohort research (cross-section “) study included 100 patients with SKR (55 were men with an average age of 57.00 ± 8.50 years old with CKD, Twenty with diabetes mellitus (DM) and nephropathy diabetics, fifteen with AHT, eleven were with chronic GMN, three with APKD, and six patients with undefined renal disease, while forty-five were female with an average age of 55.80 ± 10.50 years old), with primary kidney disease: sixteen with DM and diabetic nephron-pathy, eleven with AHT, 10-with chronic GMN; six with APCKD and four with undefined renal disease. All patients (men + women) were in the third-degree a and b according to the degree of glomerular filtration within the limits of values 30-59 mL/min/1.73 m², table number 3) with the onset of the disease 5-6 years ago. All patients were monitored in the period April-2022-April-2023.

Of the total number of patients (100) with CKD, 16 of them manifested symptoms of LN (eleven women; five men), and all fulfilled the clinical and laboratory criteria for LN according to the International Society of Nephrology (ISN)/ Renal Pathology Society (RPS), 2003/2004.

Table 2 presents the patients with CKD according to gender and average age.

Total number of patients with CKD-100	Females-45 (45%)	Males-55 (55%)
Mean age $\pm$ SD	55.80 $\pm$ 10.50 years	57.00 $\pm$ 8.50 years

Table 2. Presentation of patients with CKD according to gender and average age

Table 3 presents the patients with CKD in the third stage, with GFR of 30-59 mL/min/1.73 m² according to MDRD, gender, and underlying disease.

Patients' data	Gender	DM	AHT	Chr GMN	APCKD	Undefined
Males	55	20	15	11	3	6
Female	45	15	11	10	5	4
Total	100	35	26	21	8	10

Table 3: Presentation of patients with CKD in the third stage, GFR of 30-59 mL/min/1.73 m² according to MDRD, according to gender, underlying disease

Table 4 presents patients with LN according to classes according to the International Society of Nephrology (ISN) / Renal Pathology Society and the Renal Pathology Society (RPS) 2003/2004 (16 females-11, and males-5).

Total number (M+F) with CRD and LN= 16	Males 5	Females 11
Class I-Minimal mesangial LN	3	8
Class II-mesangial proliferative LN	1	2
Class III-Focal LN (<50% of glomerulus)	1	1

Table 4: Presentation of patients with LN according to classes according to the International Society of Nephrology (ISN) /Renal Pathology Society and the Renal Pathology Society (RPS) 2003/2004,

Statistical analysis of the examined material: The obtained results from the studied patients with CKD and the control group were statistically processed with arithmetic mean value, standard deviation $X \pm SD$, with Student's t, "t" test, Mann-Whitney and Wilcoxon test. The results were processed with the appropriate state-of-the-art statistical program, SPSS V26.

Results

Obtained at the beginning of the study (for all patients with LN and ESRD: women and men) and after 12 months of treatment are presented in Tables 5, 6, 7, and 8.

Table 5 presents results obtained from the examined parameters of patients with LN at the beginning of the study.

Examined parameters	RV	Females with LN=11	Males with LN=5
SE - mm/30 min	4-10	110 $\pm$ 10.50 $\uparrow\uparrow$	116 $\pm$ 20.00 $\uparrow\uparrow$
Hb - mmol/l	7.76-10.6	5.40 $\pm$ 0.60 $\downarrow$	6.20 $\pm$ 0.90 $\downarrow$
RBC - 10 ¹² /L	4.2-5.5	3.10 $\pm$ 0.40 $\downarrow$	3.50 $\pm$ 0.80 $\downarrow$
Htc	0,37-0,40	0.25 $\pm$ 0.30 $\downarrow$	0.36 $\pm$ 0.20 $\downarrow$
Plt - 10 ⁹ /L	140-340	90,40 $\pm$ 6.50 $\downarrow$	95.60 $\pm$ 3.80 $\downarrow$
WBC - 10 ⁹ /L	4-9	15,00 $\pm$ 2.00 $\uparrow$	17.00 $\pm$ 1.00 $\uparrow$
Neutrophils %	0.58-0.66	0.40 $\pm$ 0.30 $\downarrow$	0.45 $\pm$ 0.36 $\downarrow$
CRP- mg/l	0-50	42.00 $\pm$ 8.60 $\uparrow$	60 $\pm$ 0.40 $\downarrow$
Glycemia - mmol/l,	3.5-5.5	5.30 $\pm$ 1.00	5.20 $\pm$ 0,80
Serum Iron - μ mol/l	7.3-28	6.00 $\pm$ 1.00 $\downarrow$	6.50 $\pm$ 1.50 $\downarrow$
C3	80-128	C3<43 $\downarrow$	C3<44 $\downarrow$
C4	12-42	C4<13 $\downarrow$	C4<15 $\downarrow$
ANA	$\leq$ 1:60	>190 (positive)	>186 (positive)

Table 5. Results obtained from the examined parameters of patients with LN at the beginning of the study

Table 6 presents results obtained from the examined parameters of nitrogen degradation products in patients with LN at the beginning of the study.

Examined parameters	RV	Females with LN=11	Males with LN=5
Urea - mmol/l	2.0-8.3	16,50±10,80 ↑	16.50±10.80 ↑
Creatinine - µmol/l	F=53-88; M=71-115	170.50±18.00 ↑	180.60±15.60 ↑
Uric Acid - µmol/l	F=155-357; M=208-428	380.00±10.60 ↑	430±8,50µmol/l ↑
Proteinuria - g/24 h	<150mg/24/ 15 g/mmol	>3,6 g/24 h ↑	>3,9 g/24 h ↑
BUN	2.4-6.4 mmol/L	>9,4 ↑	>11,5 ↑
GFR	90-120 mL/min/ 1.73 m ²	50 mL/min/1.73 m ² ↓	47 mL/min/1.73 m ² ↓

Table 6. The results obtained from the examined parameters of nitrogen degradation products in patients with LN at the beginning of the study

The table of results obtained at the beginning of the study shows a disorder of all the examined parameters of the patients (F+M) with LES and LN during diagnosis and manifestations of the disease.

Table 7 presents results obtained after 12 months of LN treatment

Examined parameters	RV	Females with LN=11	Males with LN=5
SE - mm/30 min	4-10	40.00±5.00	48.00±2.00
Hb - mmol/l	7.76-10.6	6.70±1.50	7.20±1.30
RBC - 10 ¹² /L	4.2-5.5	4.10±0.80	4.80±1.00
Htc	0,37-0,40	0.35±0,40	0.42±0.60
Plt - 10 ⁹ /L	140-340	126.00±14.00	175±14.00
WBC - 10 ⁹ /L	4-9	12.00±1.30	13.60±1.00
Neutrophils %	0.58-0.66	0.54±0.80	0.60±0.30
CRP - mg/l	0-50	10.00±1.50	14.00±6.00
Glycemia - mmol/l,	3.5-5.5	5.80±1.00	5.20±0,80
Serum Iron - µmol/l	7.3-28	9.60±4.90	12.00±14.50
C3	80-128	92.00	94.00
C4	12-42	28	30
ANA	≤1:60	>170	>176

Table 7. Results obtained after 12 months of LN treatment

Table 8 presents results received from the examined parameters of nitrogen degradation products in patients with LN after 12 months of treatment

Examined parameters	RV	Females with LN=11	Males with LN=5
Urea - mmol/l	2.0-8.3	20.40±6.50	25.30±3.00
Creatinine - µmol/l	F=53-88; M=71-115	250.00±23.00	270.00±204.00
Uric Acid - µmol/l	F=155-357; M=208-428	340±9.50	410±6.00µmol/l
Proteinuria - g/24 h	<150mg/24/ 15 g/mmol	>3,0 g/24 h	>3,2 g/24 h,
BUN	2.4-6.4 mmol/L	7.6	8.2
GFR	90-120 mL/min/ 1.73 m ²	44 mL/min/1.73 m ²	40 mL/min/1.73 m ²

Table 8 The results obtained from the examined parameters of nitrogen degradation products in patients with LN after 12 months of treatment

After 12 months of treatment by the accepted recommendations and the clinical overview, improvements are observed based on the laboratory parameters examined in the patient with LN (Table 6). After treatment within 12 months with nonsteroidal anti-inflammatory drugs, low doses of Aspirin (80-160 mg/day, antimalarials-hydroxychloroquine (Plaquenil, Chloroquine, Quinacrine) or 200 mg 1-2×/day, Prednisone in quantities of 40-60 mg 1×/day (the dose was according to the clinical picture).

Azathioprine 1-2.5 mg/kg 1×/day or cyclophosphamide 4 mg/kg 1×/day was used for immunosuppression, capsules Ketosteril S.2x1, tab. CaCO₃ a 1.0 S.3x1, Rocaltrol tablets 0.5 microgram S. two days a week. The levels of C3 and C4 were significantly low, which indicates kidney damage such as the consequences of LES were manifested with lower values, which shows that the progression of the renal disease has slowed down, which demonstrates that the therapy has shown appropriate effects. High blood pressure was treated with ACE inhibitors: perindopril, fosinopril, ramipril, enalapril, trandolapril, lisinopril, benazepril, and zofenopril, each at a dose of 2x20 mg (individually with ACE inhibitor and diuretic).

Discussion

One of the most common manifestations caused by SLE is kidney damage. Out of 10 elderly SLE patients, five of them, after a few years, develop kidney damage. Lupus nephritis (LN) is a type of kidney disease caused by SLE. Lupus is an autoimmune disease with a disorder in the body's immune system that attacks the body's cells and organs. Kidney disease caused by lupus can worsen over time and lead to chronic kidney disease. 30-40% of patients with SLE manifest symptoms of nephritic syndrome, while 10% of them manifest symptoms of glomerulonephritis. With untreated SLE, initially have a slight proteinuria (<1g/day) accompanied by hematuria. Patients with membranous glomerulonephritis have proteinuria at the level of nephrotic syndrome. Still, without urinary sediment, the concentration of C3 is average, while anti-DNA, even when positive, appears in low titers.

The opposite happens with patients with proliferative nephritis who have increased proteinuria, hypertension, and improved urinary sediment; C3 is decreased, and anti-DNA is positive in high titers. The most suitable method to detect and monitor disease activity in lupus nephritis is proteinuria hematuria (microscopic and rarely macroscopic), which indicates glomerular damage of an inflammatory nature. Granular elements and fragmented erythrocytes in urine are signs of nephritic syndrome. Renal biopsy rarely affects the diagnosis of SLE, but it is the best way to document kidney damage from SLE. In the clinical picture, SLE is manifested by arterial hypertension, hyperuricemia, hyperleptinemia, low glomerular filtration rate, and the decreased titer of C3, C4, and anti-DNA (ds) positive. During the evaluation of LN, monitoring the review of the titer of complement C3 and C4 and anti-DNA (ds), which appears positive, is

essential. The progress of lupus nephritis is different in its different forms.

Significant changes in predictive parameters of the course of the disease cause the course of the disease to be different in people of other races. In general, individuals of the black race have the worst performance compared to those of the white race. An evaluation of the factors that lead to the development of CKD from LES in the initial phase (including inflammation, fibrosis of renal tissues, renal hypoxia, activation of internal kidney cells, oxidative stress...) and with quality treatment, they can affect the slowing down of the progress of the disease [16]. In most cases, LN is manifested by the deposition of immunoglobulin G (IgG) and complement in the glomeruli [17-22]. Renal damage during LN is manifested by causing mesangial hyperproliferation, matrix production, cytokine, chemokine release, and renal fibrosis through GBM damage [23].

In diseased tissues, activated glomerular endothelial cells and damaged podocytes release endothelin, accelerating MBG damage and causing mitochondrial stress and podocyte loss, leading to glomerulosclerosis. At the same time, nephrons lose compensatory mechanisms, increasing intraglomerular pressure and glomerular stress in the remaining nephrons [24-31].

The cellular components that most contribute to interstitial damage are tubular cells, lymphocytes, pericytes, fibroblasts, macrophages, endothelial cells, inflammatory lymphocytes, and infiltrating dendritic cells.

In the pathogenesis of LN, autoimmunity and immunological mechanisms that affect the production of nephrogenic autoantibodies directed against nuclear elements against nucleosome DNA, autoantibodies of specific isotypes (Ig1 and Ig3), which are deposited in glomeruli [32-35].

Therapy for managing LN should be initiated in the early stages and according to the disease classification based on the pathogenetic mechanisms. The long-term result depends on the degree of treatment response, where the resolution of proteinuria is the best indicator of a favorable prognosis. Hypertension should be managed with angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blockers (ARBs), diuretics, nonsteroidal anti-inflammatory, and antirheumatic drugs, while dyslipidemia with statins or fibrates, changes in diet (salt restriction, reduced protein consumption, not exposing to the sun) are the most common treatments for LN. Chloroquine, corticosteroid, and immunosuppressive therapy are essential in treating LN because they prevent the immune system from attacking the blood vessels in the kidneys. During the last four decades, the changes in treating LN and general medical care have greatly improved renal involvement and overall survival [36-40]. Contemporary studies have verified that T cells are the fundamental parameter in the pathogenesis of SLE through their ability to communicate with and provide exceptional assistance to B cells in inducing autoantibody production.

Several phenotypic changes that increase the propensity to activate lupus-associated inflammation have recently been identified in lupus T cells [41, 42]

Conclusion

From the obtained results, we can conclude that LES affects the appearance of renal damage. Therefore, early detection and treatment in the initial stages of LN influence the reduction of its activity in patients with CKD. Consequently, we prefer that timely treatment properly (with nonsteroidal anti-inflammatory antirheumatic, corticosteroid therapy, antimalarial, immunosuppressive therapy, ACE inhibitors or Angiotensin Receptor Blockers (ARBs and antilepemic in patients with pre-uremia should be the main goals and objectives of nephrologists, rheumatologists and dermatovenerologists to prevent progression of the disease towards end-stage chronic renal failure.

COI Statement: This paper has yet to be submitted in parallel, presented fully or partially at a meeting podium or congress, or published or submitted for consideration beforehand.

This research received no specific grant from any funding agency in the public, commercial, or non-profit sectors. There are no relevant or minor financial relationships with external companies from authors, their relatives, or next of kin.

Disclosure: The authors declared no conflict of interest. No funding was received for this study

Abbreviations;

Lupus Nephritis - LN; *Systemic Lupus Erythematosus* - SLE; *Antibodies Antinuclear* - ANA; *Lupus Erythematosus Systemic* - LES; *End Stage Chronic Renal Disease* - ESRD; *Haemodialysis* - HD; *Glomerular Filtration Rate* - GFR; *Chronic Kidney Disease* - CKD; *Diabetes Mellitus* - DM; *Arterial Hypertension* - AHT; *Chronic Glomerulonephritis (CGN)*; *Adult Polycystic Kidney Disease* - APCKD; *International Society of Nephrology* - ISN; *Renal Pathology Society* - RPS; *chronic glomerulonephritis* - chr GMN; *Sediment* - SE; *Haemoglobin* - Hb; *Red Blood Cells* - RBC; *Haematocrit* - Htc; *Platelets* - Plt; *White Blood Cells* - WBC; *C-Reactive Protein* - CRP; *Reference values* - RV; *Complement Fraction 3* - C3; *Complement Fraction 4* - C4; *Blood Urea Nitrogen* - BUN; *National Kidney Foundation* - NKF; *Immunoglobulin G* - IgG; *Angiotensin II Receptor Blockers* - ARB; *Angiotensin-Converting Enzyme* - ACE; *Glomerular Basement Membrane* - GBM;

References

1. Elliot V, Cairns T, Cook HT. Evolution of lesions over 10 years in a patient with SLE: flowchart approach to the new International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of lupus nephritis. *Am J Kidney Dis.* 2006 Jan;47(1):184–90. doi: 10.1053/j.ajkd.2005.06.027. PMID: 16377401.
2. Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN. Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. *Lupus.* 2010 Apr;19(5):557–74. doi: 10.1177/0961203309358187. Epub 2010 Jan 20. PMID: 20089610.
3. Lupus nephritis: Symptoms, treatment, and complications. American Kidney Fund May 31, 2023. Manifestations of lupus in the kidney and how to manage them. *Nephrology Dialysis Transplantation*, Volume 32, Issue 10, October 2017, Pages 1614–1616,
4. Weening JJ, D'Agati VD, Schwartz MM, et al. International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. *Kidney Int.* 2004 Feb;65(2):521–30. doi: 10.1111/j.1523-1755.2004.00443.x. Erratum in: *Kidney Int.* 2004 Mar;65(3):1132. PMID: 14717922.
5. Weening J.J., D'Agati V.D., Schwartz M.M., et al. Classification of glomerulonephritis in systemic lupus erythematosus revisited. *J Am Soc Nephrol*, 15 (2004), pp. 241–250.
6. Churg, J. and Sobin, L. (1982) renal disease: Classification and Atlas of Glomerular Disease. Igaku-Shoin, Tokyo.
7. J. Churg, J. Bernstein, R.J. Glasscock. renal disease: Classification and Atlas of Glomerular Disease (2nd ed), Igaku-Shoin, New York (1995)
8. Furness P.N., Taub N. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis – A UK-wide study. *Am J Surg Pathol.* 2006; 30: 1030–1035.
9. Zickert A, Sundelin B, Svenungsson E, Gunnarsson I. Role of early repeated renal biopsies in lupus nephritis. *Lupus Sci Med.* 2014;1(1):e000018.
10. Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN. Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. *Lupus.* 2010;19(5):557–74.
11. Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus (<https://pubmed.ncbi.nlm.nih.gov/27442661/>). *Medicine.* 2016 July;95(29): e4272.
12. Lupus Foundation of America. What is lupus nephritis (<https://www.lupus.org/reso-urces/what-is-lupus-nephritis/>)? Accessed 9/22/2021.

13. Lupus Foundation of America. What is lupus(<https://www.lupus.org/resources/what-is-lupus>)? Accessed 9/22/2021.
14. National Kidney Foundation. Lupus and Kidney Disease (Lupus Nephritis) (<https://www.kidney.org/atoz/content/lupus>). We accessed 9/22/2021.
15. Austin HA. Clinical evaluation and monitoring of lupus kidney disease. *Lupus* 1998; 7:618-21.
16. Anne Davidson: What is damaging the kidney in lupus nephritis? *Nat Rev Rheumatol*. 2016 Mar; 12(3): 143–153.
17. Madaio MP. The role of autoantibodies in the pathogenesis of lupus nephritis. *Semin Nephrol*. 1999;19(1):48–56.
18. Hedberg A, Mortensen ES, Rekvig OP. Chromatin as a target antigen in human and murine lupus nephritis. *Arthritis Res Ther*. 2011;13(2):214.
19. Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins complexes. J FA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune Clin Invest. 2004;114(5):679–88.
20. Ullal AJ, Reich CF, 3rd, Clowse M, Criscione-Schreiber LG, Tochacek M, Monestier M, et al. Microparticles are antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. *J Autoimmun*. 2011;36(3–4):173–80.
21. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. *Proc Natl Acad Sci U S A*. 2010;107(21):9813–8.
22. Seredkina N, Rekvig OP. Acquired loss of renal nuclease activity is restricted to DNaseI and is an organ-selective feature in murine lupus nephritis. *Am J Pathol*. 2011;179(3):1120–8.
23. Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. *Am Soc Nephrol*. 2008;19(1):12–23.
24. Daehn I, Casalena G, et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. *J Clin Invest*. 2014;124(4):1608–21.
25. Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. *Kidney Int*. 2005;67(2):404–19.
26. Bergtold A, Gavhane A, D'Agati V, et al. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. *J Immunol*. 2006;177(10):7287–95.
27. Perez de Lema G, Maier H, Nieto E, et al. Chemokine expression precedes inflame-memory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. *J Am Soc Nephrol*. 2001;12(7):1369–82.
28. Segerer S, Schlondorff D. Role of chemokines for the localization of leukocyte subsets in the kidney. *Semin Nephrol*. 2007; 27(3):260–74.
29. Vandepapeliere J, Aydin S, Cosyns JP, et al. Prognosis of proliferative lupus nephritis subsets in the Louvain Lupus Nephritis Inception Cohort. *Lupus*. 2014;23(2):159–65.
30. Dall'Era M, Cisternas M, Smilek D, et al. Predictors of long-term renal outcome in Lupus Nephritis Trials: Lessons learned from the Euro-Lupus Nephri. Cohort. *Arthritis Rheum*. 2015 May;67(5):1305–13.
31. Yung S, Chan TM. Anti-DNA antibodies in the pathogenesis of lupus nephritis--the emerging mechanisms. *Autoimmun Rev*. 2008 Feb. 7(4):317–21.
32. Davidson A, Berthier C, Kretzler M. Pathogenetic mechanisms in lupus nephritis. Wallace DJ, Hahn BH, eds. *Dubois' Lupus Erythematosus and Related Syndromes*. 8th ed. Philadelphia, PA: Elsevier Saunders; 2013. 237–55.
33. Grande JP. Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. *Lupus*. 1998. 7(9):604–10.
34. Lisnevskaja L, Murphy G, Isenberg D. Systemic lupus erythematosus. *Lancet*. 2014 Nov 22. 384 (9957):1878–1888.
35. Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to disease-activity-associated expansions and immunity to a gut commensal. *Ann Rheum Dis*. 2019 Feb 19.
36. Berthier CC, Bethunaickan R. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. *J Immunol*. 2012;189(2):988–1001.
37. Lawrence H Brent, MD; Chief Editor: Vecihi Batuman, MD, *Lupus Nephritis*. 27, 2023. Medscape
38. Dooley MA. Clinical and epidemiologic features of lupus nephritis. Wallace DJ, Hahn BH, eds. *Dubois' Lupus Erythematosus and Related Syndromes*. 8th ed. Philadelphia, PA: Elsevier Saunders; 2013. 438–54.
39. Pons-Estel GJ, Alarcón GS, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. *Arthritis Rheum*. 2009 Jun 15. 61 (6):830–9.
40. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. *Lupus*. 2008. 17(5):426–30.
41. Liu Z, Davidson A. (2011). BAFF and selection of autoreactive B cells. *Trends in Immunology*;32(8):388–394.
42. Shlomchik MJ, Craft JE, Mamula MJ. (2001). From T to B and back: positive feedback in systemic autoimmune disease. *Nature Reviews Immunology* ;1(2): 147–153